Experimental therapies for multiple sclerosis: Current status

Cleveland Clinic Journal of Medicine

Volumn 59, Issue 1, 1992, Pages 63-74

  Goodkin, D E ^a   Ransohoff, R M ^a   Rudick, R A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FOLIC ACID; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 3; METHOTREXATE; METHYLPREDNISOLONE; MIGRATION INHIBITION FACTOR; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR;

ALOPECIA; CLINICAL TRIAL; DISEASE SEVERITY; GINGIVA HYPERPLASIA; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; LYMPH NODE IRRADIATION; MULTIPLE SCLEROSIS; NAUSEA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PARESTHESIA; PLASMAPHERESIS; REVIEW; SIDE EFFECT; TOXICITY; VOMITING;

EID: 0026556478     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.59.1.63     Document Type: Review

References (0)